RAPP
Rapport Therapeutics Inc

378
Mkt Cap
$1.39B
Volume
96,574.00
52W High
$42.27
52W Low
$7.73
PE Ratio
-10.12
RAPP Fundamentals
Price
$27.90
Prev Close
$29.00
Open
$29.06
50D MA
$28.08
Beta
1.44
Avg. Volume
286,131.96
EPS (Annual)
-$2.86
P/B
2.86
Rev/Employee
$0.00
$702.11
Loading...
Loading...
News
all
press releases
All You Need to Know About Rapport Therapeutics, Inc. (RAPP) Rating Upgrade to Buy
Rapport Therapeutics, Inc. (RAPP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks·23h ago
News Placeholder
More News
News Placeholder
Baker BROS. Advisors LP Has $45.95 Million Position in Rapport Therapeutics, Inc. $RAPP
Baker BROS. Advisors LP grew its stake in shares of Rapport Therapeutics, Inc. (NASDAQ:RAPP - Free Report) by 181.2% during the 3rd quarter, according to the company in its most recent filing with...
MarketBeat·12d ago
News Placeholder
Rapport Therapeutics (NASDAQ:RAPP) Downgraded to "Sell" Rating by Wall Street Zen
Wall Street Zen lowered Rapport Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday...
MarketBeat·13d ago
News Placeholder
Q1 EPS Estimate for Rapport Therapeutics Lifted by Analyst
Rapport Therapeutics, Inc. (NASDAQ:RAPP - Free Report) - Research analysts at HC Wainwright raised their Q1 2026 earnings estimates for Rapport Therapeutics in a research note issued to investors on...
MarketBeat·14d ago
News Placeholder
Rapport Therapeutics (NASDAQ:RAPP) Stock Price Down 7.7% - Should You Sell?
Rapport Therapeutics (NASDAQ:RAPP) Shares Down 7.7% - Here's What Happened...
MarketBeat·15d ago
News Placeholder
Equities Analysts Offer Predictions for RAPP FY2030 Earnings
Rapport Therapeutics, Inc. (NASDAQ:RAPP - Free Report) - Equities researchers at HC Wainwright issued their FY2030 earnings per share (EPS) estimates for Rapport Therapeutics in a research report...
MarketBeat·15d ago
News Placeholder
Rapport Therapeutics (NASDAQ:RAPP) Price Target Raised to $46.00 at Wells Fargo & Company
Wells Fargo & Company upped their target price on Rapport Therapeutics from $43.00 to $46.00 and gave the company an "overweight" rating in a report on Wednesday...
MarketBeat·16d ago
News Placeholder
Rapport Therapeutics (NASDAQ:RAPP) Shares Gap Down on Disappointing Earnings
Rapport Therapeutics (NASDAQ:RAPP) Shares Gap Down Following Weak Earnings...
MarketBeat·17d ago
News Placeholder
Cheryl Gault Sells 2,014 Shares of Rapport Therapeutics (NASDAQ:RAPP) Stock
Rapport Therapeutics, Inc. (NASDAQ:RAPP - Get Free Report) COO Cheryl Gault sold 2,014 shares of the firm's stock in a transaction that occurred on Thursday, March 5th. The stock was sold at an...
MarketBeat·18d ago
News Placeholder
Rapport Therapeutics (RAPP) to Release Quarterly Earnings on Tuesday
Rapport Therapeutics (NASDAQ:RAPP) will be releasing its Q4 2025 earnings before the market opens on Tuesday, March 10. (View Earnings Report at...
MarketBeat·24d ago
<
1
2
...
>

Latest RAPP News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.